In this episode of Clinical Lab Chat, CLP’s Director of Business Intelligence, Chris Wolski, discusses the how and why of making precise clinical diagnosis of neurodegenerative diseases with Russ Lebovitz, MD, PhD, co-founder and CEO of Amprion. Among the topics they discuss:The critical importance of making accurate diagnoses of neurodegenerative diseasesWhy alpha-synuclein is an accurate biomarker for a number of degenerative diseases, including Alzheimer’sHow adding neurodegenerative testing to the routine diagnostic menu would benefit patients and their caregiversWhy we’re entering a neurological healthcare “golden age”
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Advancements in HLA Matching and Antibody Detection
What Do the New ASCCP Guidelines Mean for Clinical Labs?
C Diff: How Awareness Improves Diagnostics and Treatments
HPV Self-Sampling Is Being Put into Practice in Texas
Free AI-powered recaps of Clinical Lab Chat and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.